What s New for People Living With HoFH
|
|
- Logan Clark
- 6 years ago
- Views:
Transcription
1 What s New for People Living With HoFH (Homozygous Familial Hypercholesterolemia)? An innovative experimental gene therapy treatment for HoFH Learn about the ongoing gene therapy clinical trial in HoFH
2 What Is HoFH? Familial hypercholesterolemia (FH) is a life-threatening genetic disorder. In people with FH, a genetic mutation impairs the liver s ability to capture and remove low-density lipoprotein cholesterol (-C), the bad cholesterol, from the blood. High levels of -C result in a buildup of cholesterol and plaque in the arteries, known as atherosclerosis, which may lead to heart disease and stroke. In FH, one genetic mutation is inherited. Homozygous familial hypercholesterolemia (HoFH) is a rare and severe form of FH, where two genetic mutations are inherited. People with HoFH have extremely high levels of -C in their blood and can suffer serious cardiac events before the age of 30. receptor liver cell Normal receptors (Rs) capture and remove -C from the blood, keeping -C at a safe level. receptor liver cell HoFH People with HoFH have defective or missing receptors in their liver; as a result, -C builds up in their blood. Patients with HoFH need lifelong therapy (often combination therapy) to lower their -C levels and prevent or delay serious health problems, such as heart disease and stroke.
3 Gene Therapy for HoFH A new experimental treatment that has the potential to deliver functional copies of the human R gene to the liver Genetic disorders are often caused by a defective gene. The defective gene may then produce a protein that does not function properly. In people with HoFH, the R gene is defective, meaning the Rs that the gene produces are missing or do not function properly. Gene therapy is an experimental treatment that has the potential to deliver to the cells a healthy R gene using a modified virus, called AAV8, as a delivery vehicle. In people with HoFH the modified virus transports copies of the healthy R gene to the liver. Once in the liver, the healthy gene is expected to make functional Rs.
4 How It Works: 1 A functional copy of the R gene is packaged in a modified virus called AAV8,* which acts like an envelope to carry the gene to the cells. This delivery vehicle is called a viral vector. * The virus used is not known to cause disease in humans. intravenous injection 2 The AAV8 vector is given by a single intravenous injection into the bloodstream, where it is expected to travel to the liver. 3 Once the AAV8 vector reaches the liver, it is intended to deliver the functional gene to the liver cells, enabling the cells to make the R protein it needs. The viral envelope leaves the body and the R remains. 4 The liver is then expected to capture and remove -C from the blood to prevent the buildup of bad cholesterol.
5 Why Consider Gene Therapy? Current treatments for HoFH may not lower cholesterol to optimal levels. Medications are taken for life and may not be well tolerated and/or have limited results Lipoprotein apheresis, a procedure that removes -C from the blood, needs to be administered every 1 to 2 weeks Liver transplants are high risk and rare Gene therapy is an experimental treatment requiring a single administration that may have a long-lasting effect on -C levels. The HoFH Gene Therapy Clinical Trial The University of Pennsylvania is recruiting adults for a Phase I/II clinical trial in people with HoFH. Genetic testing will be done to confirm if patients are eligible. The goal of this clinical trial is to show the safety of and potential long-lasting results from a single intravenous injection. Safety Gene therapy has shown promise in people living with another genetic disorder called hemophilia. Learn More Screening for this clinical trial is now in progress. For more information, contact: Marina Cuchel, MD, PhD at mcuchel@mail.med.upenn.edu or (215) ; Canita Brent at cbrent@mail.med.upenn.edu or (215) ; or visit Participation Ask your doctor if you or a loved one is eligible for this trial. Contact the University of Pennsylvania and visit
6
KNOWHoFH. Your guide to homozygous familial hypercholesterolaemia (HoFH)
GET KNOWHoFH TO Your guide to homozygous familial hypercholesterolaemia (HoFH) Welcome You re receiving this educational guide because you or someone in your family has been diagnosed with homozygous familial
More informationFamilial Hypercholesterolemia
Understanding (FH) Familial Hypercholesterolemia For more information, visit Understanding Familial Hypercholesterolemia (FH) Your doctor may have told you that too much of the bad type of cholesterol
More informationElements for a Public Summary. PhV Page 54/143
VI.2 Elements for a Public Summary PhV-20141675 Page 54/143 VI.2.1 Overview of disease epidemiology Hypercholesterolaemia Hypercholesterolemia (high levels of cholesterol in the blood) is usually discovered
More informationCommon Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2
Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationFamilial Hypercholesterolemia
Familial Hypercholesterolemia Dr.Ramzi Al-Mohammadi Assistant Professor of Medicine Interventional Cardiologist, Advanced HF and Transplant Consultant Classification of Hyperlipedemia Primary hyperlipedemia:
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationInspired Functional Ingredients to Innovate and Differentiate Your Brand. Products by Ecovatec Solutions Inc.
Inspired Functional Ingredients to Innovate and Differentiate Your Brand Products by Ecovatec Solutions Inc. High Density Lipopeptides (HDL p ) High Density Lipopeptides (HDL p ) High density lipoproteins
More informationThe benefit of knowing
The benefit of knowing Genetic testing for familial hypercholesterolemia (FH) A patient support guide 2 Does high cholesterol run in your family? In some families, high cholesterol is caused by familial
More informationEzetimib Stada 10 mg tablets
Ezetimib Stada 10 mg tablets 13.7.2016, Version V1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Ezetimib Stada 10 mg tablets VI.2.1 Overview of disease epidemiology Having
More informationThe identification and management of heterozygous familial hypercholesterolaemia in adults, young people and children (QS41)
QS 41 The identification and management of heterozygous familial hypercholesterolaemia in adults, young people and children (QS41) NICE provided the content for this booklet which is independent of any
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationElements for a Public Summary
VI.2 Elements for a Public Summary / / 10 mg/10 mg tablets / / 10 mg/20 mg tablets / / 10 mg/40 mg tablets / / 10 mg/80 mg tablets VI.2.1 Overview of disease epidemiology Prevention of cardiovascular events
More informationNHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell
NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell Aim of the session 1. Increase your understanding of the cardiovascular system 2. Describe the most common
More information*Carbohydrate & Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa
Tuesday, May 26, 2015 Clinical Breakthroughs: Modifying LDL Cholesterol to Prevent CV Events International Society of Atherosclerosis, Amsterdam, Netherlands Long-term Treatment With Evolocumab in Patients
More informationA Phase 3 Study of Lomitapide, a Microsomal Triglyceride Transfer Protein (MTP) Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia
A Phase 3 Study of Lomitapide, a Microsomal Triglyceride Transfer Protein (MTP) Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia Marina Cuchel, MD, PhD University of Pennsylvania, Philadelphia,
More informationTreatment of severe Familial Hypercholesterolemia LDL Apheresis
Treatment of severe Familial Hypercholesterolemia LDL Apheresis Identifying and Treating Severe Familial Hypercholesterolemia October 14-15, 2017 Dubai, UAE Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior
More informationMedication Policy Manual. Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru302 Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: April 1, 2015 IMPORTANT
More informationIdentification and management of familial hypercholesterolaemia (FH) - An overview
Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August
More informationCHOLESTEROL CONTENT CREATED BY. Learn more at
CHOLESTEROL CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents what is cholesterol? 4 Whether this is your first visit or a follow-up, asking your doctor these
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationFrom Biology to Therapy The biology of PCSK9 in humans Just LDL-cholesterol or more? May 24th. Dr. Gilles Lambert
Dr. Gilles Lambert Associate Professor in Cell Biology University of Nantes Medical School Group Leader, Laboratory of Nutrition and Metabolism, University Hospital of Nantes From Biology to Therapy The
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: September 15, 2017 Kynamro Description Kynamro
More informationYour cholesterol levels. Questions or concerns
Because you have high cholesterol you should: Know your cholesterol levels Take the medicine to lower cholesterol that your doctor has told you to take Follow your doctor s treatment plan Keep your appointments
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: December 2, 2016 Kynamro Description Kynamro (mipomersen)
More informationFACT SHEET 53. What is inherited predisposition to cardiovascular disease?
Important points One form of cardiovascular disease is coronary artery disease that results from a build up of cholesterol and other fats in the blood causing the formation of plaques. Plaque deposits
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Ezetimibe/simvastatin is used to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD). CHD occurs
More informationPCSK9 inhibition in homozygous familial hypercholesterolaemia
PCSK9 inhibition in homozygous familial hypercholesterolaemia Slide deck kindly supplied as an educational resource by Dr Evan A Stein MD PhD Director Emeritus Metabolic & Atherosclerosis Research Center
More informationFamilial hypercholesterolaemia
Familial hypercholesterolaemia Jaimini Cegla MRCP FRCPath PhD Consultant in Chemical Pathology and Metabolic Medicine Hammersmith Hospital Lipid Clinic 20 April 2017 An unrecognised, potentially fatal,
More informationMedication Policy Manual Policy No: Topic: Date of Origin: Committee Approval Date: Next Review Date: Effective Date: IMPORTANT REMINDER Description
Medication Policy Manual Policy No: dru301 Topic: Kynamro, mipomersen Date of Origin: May 16, 2013 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: April 1, 2015 IMPORTANT
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationWORKSHOP 1. Management of Patients with Familial Hypercholesterolemia
WORKSHOP 1 Management of Patients with Familial Hypercholesterolemia Tutors: Manal Al-Kindi (Oman)/ Gilles Lambert (France) (Case 1) Zuhier Awan (KSA)/ Raul Santos (Brazil) (Case 2) Khalid Al-Waili (Oman)/
More informationJuxtapid. Juxtapid (lomitapide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Juxtapid Page: 1 of 6 Last Review Date: September 20, 2018 Juxtapid Description Juxtapid (lomitapide)
More informationHeart Disease. Signs and Symptoms
Heart Disease The term "heart disease" refers to several types of heart conditions. The most common type is coronary artery disease, which can cause heart attack, angina, heart failure, and arrhythmias.
More informationDrug Regulatory Affairs. Praluent. Summary of the Risk Management Plan (RMP) for Praluent (alirocumab)
Drug Regulatory Affairs Praluent Summary of the Risk Management Plan (RMP) for Praluent (alirocumab) Document version: 02 Document date: MAY 2018 Summary of the risk management plan (RMP) for Praluent
More informationAn educational booklet for patients with familial hypercholesterolemia DR. LEIV OSE
An educational booklet for patients with familial hypercholesterolemia DR. LEIV OSE CONTENTS WHAT WILL YOU LEARN FROM THIS BOOKLET? You will learn about Familial Hypercholesterolemia, its cause, and the
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationAppendix F Simon Broome Diagnostic criteria for index individuals and relatives
Appendix F Simon Broome Diagnostic criteria for index individuals and relatives 1 SIMON BROOME DIAGNOSTIC CRITERIA FOR INDEX INDIVIDUALS (PROBANDS) 2 2 GENDER- AND AGE-SPECIFIC LDL-C CRITERIA FOR THE DIAGNOSIS
More informationWest Midlands Familial Hypercholesterolaemia Service
Elaine George WMFHS Clinical Programme Manager West Midlands Familial Hypercholesterolaemia Service Elaine George WMFHS Clinical Programme Manager PCCS Conference November 2018 1 Presentation Objectives
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationI have made it my personal mission to find out everything I can to ensure my father and the thousands of other are living well with heart disease.
About the Author: Heart disease is the leading cause of death of men and women yet the number one preventable disease. My name is Diamond Fernandes and as a cardiac exercise physiologist, I absolutely
More informationAlso, some risk factors, such as smoking and diabetes, put you at greater risk for CHD and heart attack than others.
Who is at Risk for Heart Disease? Certain traits, conditions, or habits may raise your risk for coronary heart disease (CHD). These conditions are known as risk factors. Risk factors also increase the
More informationRequest for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax
Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density
More informationFamilial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
More informationFamilial Hypercholeterolaemia
Familial Hypercholeterolaemia Is it all about statins? Gerald F Watts DSc PhD MD FRACP FRCP Professor and Head, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital School of Medicine,
More informationEvaluating Residual Risk and Long-term Management of the Young CHD Patient. The Arterial Wall
Evaluating Residual Risk and Long-term Management of the Young CHD Patient Patrick M Moriarty, M.D., Professor of Medicine Director of Clinical Pharmacology, Atherosclerosis and Lipoprotein-apheresis Center
More informationHoFH presents with a wide spectrum of LDL-C levels in a genetically confirmed cohort of patients
HoFH presents with a wide spectrum of LDL-C levels in a genetically confirmed cohort of patients Claudia Stefanutti Department of Molecular Medicine, Sapienza University Rome, Italy HoFH, homozygous familial
More informationNutrition & Wellness for Life 2012 Chapter 6: Fats: A Concentrated Energy Source
Tools: Printer 8.5 x 11 paper Scissors Directions: 1. Print 2. Fold paper in half vertically 3. Cut along dashed lines Copyright Goodheart-Willcox Co., Inc. All rights reserved. Tissue in which the body
More informationMY CHOLESTEROL GUIDE. Take Action. Live Healthy! heart.org/cholesterol
MY CHOLESTEROL GUIDE Take Action. Live Healthy! heart.org/cholesterol UNDERSTANDING AND MANAGING CHOLESTEROL CONTENTS Understanding Risk...3 Why Am I at Risk?...3 How Will My Risk Factors Be Treated?...4
More informationEpidemiology: Prevention and Control of Diseases and Health Conditions. Chapter 4
Epidemiology: Prevention and Control of Diseases and Health Conditions Chapter 4 Introduction Disease classification can lead to prevention and control. In community health, classification is usually Acute
More informationA Guide for Understanding Genetics and Health
2 Does it Run in the Family? A Guide for Understanding Genetics and Health brookdale hospital and medical center Contents Why is genetics important to my family and me? 1 What makes me unique? 2 Tell me
More information34% of men (ranging from 21% - 41% in different regions) and 40% in women (ranging from 26% - 47% in different regions). [Ref. 5.
VI.2 PAGE 174 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hypercholesterolemia (or hyperlipidaemia) refers to high blood cholesterol levels. Cholesterol is a waxy, fatty substance
More informationAdvanced Biology Mrs. Amspoker Blizzard Bag #2. Using Family History to Improve Your Health Web Quest
Advanced Biology Mrs. Amspoker Blizzard Bag #2 Using Family History to Improve Your Health Web Quest Learning Objectives Chronic diseases such as heart disease, cancer, and diabetes, run in families. An
More informationNutrition, Food, and Fitness. Chapter 6 Fats: A Concentrated Energy Source
Nutrition, Food, and Fitness Chapter 6 Fats: A Concentrated Energy Source Tools: Printer (color optional) 4 sheets of 8.5 x 11 paper Scissors Directions: 1. Print 2. Fold paper in half vertically 3. Cut
More information1. Most of your blood cholesterol is produced by: a. your kidneys b. your liver c. your pancreas d. food consumption (Your liver)
I. TEST YOUR KNOWLEDGE OF CHOLESTEROL Choose the correct answer. 1. Most of your blood cholesterol is produced by: a. your kidneys b. your liver c. your pancreas d. food consumption (Your liver) 2. Only
More informationFamilial Hypercholesterolemia New treatments
Familial Hypercholesterolemia New treatments Prof. Shlomo Keidar Head Internal Medicine A Rambam Health Care Campus IAS, Haifa May 2013 Effect of treatment on CV survival in Familial Hypercholesterolemia
More informationIntroduction 3. What is Peripheral Vascular Disease? 5. What Are Some of the Symptoms of Peripheral Vascular Disease? 6
Patient Information Table of Contents Introduction 3 What is Peripheral Vascular Disease? 5 What Are Some of the Symptoms of Peripheral Vascular Disease? 6 What Causes Peripheral Vascular Disease? 7 How
More informationPCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia
PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;
More informationSummary of the risk management plan (RMP) for Praluent (Alirocumab)
EMA/519153/2015 Summary of the risk management plan (RMP) for Praluent (Alirocumab) This is a summary of the risk management plan (RMP) for Praluent, which details the measures to be taken in order to
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationExcess calcium in the heart
Excess calcium in the heart 27-5-2014 Are You Taking Too Much Calcium, A or D?. There, it helps form plaques that threaten the heart and brain. Excess calcium can also cause muscle pain,. TEENney stones,
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationLDL Apheresis: Familial Hypercholesterolemia
LDL Apheresis: Familial Hypercholesterolemia Joyce L Ross, MSN, CRNP, CCS, FNLA, FPCNA Certified Clinical Specialist, Diplomat ACCL Past President PCNA Immediate Past President National Lipid Association
More informationPatient Group Input Submissions
CADTH COMMON DRUG REVIEW Patient Group Input Submissions EVOLOCUMAB (Repatha) (Amgen Canada Inc.) Indication: As an adjunct to diet and maximally tolerated statin therapy in adult patients with heterozygous
More informationLIPOPROTIEN APHERESIS. Bruce Sachais, MD, PhD Executive Medical Director New York Blood Center
LIPOPROTIEN APHERESIS Bruce Sachais, MD, PhD Executive Medical Director New York Blood Center OUTLINE Familial Hypercholesterolemia (FH) Diagnosis Treatment options Lipoprotein apheresis Procedures Expected
More informationIntroduction. Every organism must exchange materials and energy with its environment, and this exchange ultimately occurs at the cellular level.
Introduction Every organism must exchange materials and energy with its environment, and this exchange ultimately occurs at the cellular level. Cells live in aqueous environments. The resources that they
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Repatha) Reference Number: HIM.PA.SP46 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationCorporate Medical Policy Lipid Apheresis
Corporate Medical Policy Lipid Apheresis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: lipid_apheresis 11/2013 4/2017 4/2018 5/2017 Description of Procedure or Service Therapeutic
More informationFOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?
FOURIER STUDY Did the study achieve its main objective? 2 15% 1 5% 9.8% YES FOURIER compared Repatha with placebo in patients who were taking a statin and had hardening or narrowing of the arteries and
More informationThe Addition of Ezetimibe to Statin therapy in. Patients with Homozygous Familial. Hypercholesterolaemia
The Addition of Ezetimibe to Statin therapy in Patients with Homozygous Familial Hypercholesterolaemia Submitted in fulfilment with the requirements for the degree Master in Medicine (MMed) Dr Adriano
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationStudents will identify factors that affect blood flow and/or describe how these factors affect blood flow through the cardiovascular system.
Students will identify factors that affect blood flow and/or describe how these factors affect blood flow through the cardiovascular system. Content Limits Items may address factors such as blood pressure,
More informationNHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell
NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell Aim of the session 1. Understanding of the cardiovascular system 2. Describe the most common types of
More informationJuxtapid and Kynamro
DRUG POLICY Juxtapid and Kynamro BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017
Clinical Policy: (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationab LDL Uptake Assay Kit (Cell-Based)
ab133127 LDL Uptake Assay Kit (Cell-Based) Instructions for Use For the detection of LDL uptake into cultured cells. This product is for research use only and is not intended for diagnostic use. Version
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels
More informationA Guide for Understanding Genetics and Health
2 Does it Run in the Family? A Guide for Understanding Genetics and Health National Council of La Raza Contents Why is genetics important to my family and me? 1 What makes me unique? 2 Tell me more about
More informationKynamro (mipomersen)
Kynamro (mipomersen) Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201803/01/2019 POLICY A. INDICATIONS The indications below including
More informationGlossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:
Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationA Guide for Understanding Genetics and Health
2 Does it Run in the Family? A Guide for Understanding Genetics and Health INTERMOUNTAIN HEALTHCARE Contents Why is genetics important to my family and me? 1 What makes me unique? 2 Tell me more about
More informationChapter 18. Diet and Health
Chapter 18 Diet and Health Risk Factors and Chronic Diseases Interrelationships among Chronic Diseases Chronic Disease Heart Disease and Stroke Hypertension Cancer Diabetes The Formation of Plaques in
More informationCARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE
CARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE AFTER YOUR LOVED ONE HAS HAD A HEART ATTACK OR STROKE Heart attack and stroke affects the whole family. If your loved one has had a heart attack or
More informationA Guide for Understanding Genetics and Health
2 Does it Run in the Family? A Guide for Understanding Genetics and Health u n i v e r s i t y o f o k l a h o m a health sciences center Contents Why is genetics important to my family and me? 1 What
More informationFocus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013
Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013 Conflicts CMO for The FH Foundation Pre-talk quiz What is cascade screening? 1. screening all family members 2.
More informationAtherosclerosis. Atherosclerosis happens when the blood vessels
Atherosclerosis Atherosclerosis happens when the blood vessels that carry oxygen and nutrients from your heart to the rest of your body (arteries) become thick and stiff sometimes restricting blood flow
More informationEmerging low-density lipoprotein therapies: Microsomal triglyceride transfer protein inhibitors
Journal of Clinical Lipidology (2013) 7, S16 S20 Emerging low-density lipoprotein therapies: Microsomal triglyceride transfer protein inhibitors Anne C. Goldberg, MD, FACP, FAHA, FNLA* Associate Professor
More informationARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk
ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk CONSIDER YOUR HEART HEALTH: REDUCE YOUR CHOLESTEROL Uncontrolled or continuous high cholesterol
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationVery high cholesterol from birth: are target LDL cholesterol levels now achievable with new treatments?
Press release 3 Madrid, May 3 st, 204 82 nd Annual Congress of the European Atherosclerosis Society (EAS) May 3-June 3, Madrid, Spain Very high cholesterol from birth: are target LDL cholesterol levels
More informationFamilial hypercholesterolaemia Your quick guide
Familial hypercholesterolaemia Your quick guide Coronary heart disease is the UK s single biggest killer. For over 50 years we ve pioneered research that s transformed the lives of people living with heart
More informationHeart Health C M Y K. Fotolia
Heart Health C M Y K Fotolia PAGE 2 HEART HEALTH RECOVERY Life After Heart Attack O vercoming a heart attack may seem like an overwhelming feat. While it will be a lifelong recovery, you can still live
More informationCLASSROOM ACTIVITIES. THE HEART Student Pages. Designers Brianne Miller, Molly Bugaile
CLASSROOM ACTIVITIES THE HEART Student Pages Designers Brianne Miller, Molly Bugaile The heart is the most important muscle in the body! Heart Activity I Just beat it! The heart is the most important muscle
More informationEVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378
Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 This drug requires a written request for prior authorization. All requests for Repatha (evolocumab) require review by a pharmacist prior
More information